Shattuck Labs, Inc. (STTK) Stock Ticker
STTK right now
Market factors today
Unlock the full STTK picture
About Shattuck Labs, Inc.
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
STTK stock facts
| Ticker symbol | STTK |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $548.6M |
| CEO | Taylor H. Schreiber |
| Employees | 40 |
| Headquarters | Austin, TX, US |
| IPO date | 2020-10-09 |
| Website | www.shattucklabs.com |
What you can see for STTK on Tickr
Live STTK price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the STTK report.
Rankings
FAQ
What is the ticker symbol for Shattuck Labs, Inc.?
The ticker symbol for Shattuck Labs, Inc. is STTK, listed on the NASDAQ Global Select.
What is STTK?
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and…